Abstract
P552 Association between Week 8 Mayo subscores and hospitalisation rates in adalimumab-treated patients with ulcerative colitis from ULTRA 1 and ULTRA 2 W. Reinisch1 *, W.J. Sandborn2, B. Feagan3, S. Ghosh4, A. Robinson5, M. Skup5, J. Petersson5, B. Huang5, A. Lazar6, R. Thakkar5. 1McMaster University, Department of Medicine, Hamilton, Canada, 2University of California San Diego, Division of Gastroenterology, La Jolla, United States, 3Robarts Clinical Trials Inc., Robarts Research Institute, Western University, London, Ontario, Canada, 4University of Calgary, Department of Medicine, Calgary, Canada, 5AbbVie Inc, GPRD, North Chicago, United States, 6AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
